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The periaxin gene (PRX) encodes two PDZ-domain proteins, L- and S-periaxin, that are required for maintenance
of peripheral nerve myelin. Prx5/5 mice develop a severe demyelinating peripheral neuropathy, despite apparently
normal initial formation of myelin sheaths. We hypothesized that mutations in PRX could cause human peripheral
myelinopathies. In accordance with this, we identified three unrelated Dejerine-Sottas neuropathy patients with
recessive PRX mutations—two with compound heterozygous nonsense and frameshift mutations, and one with a
homozygous frameshift mutation. We mapped PRX to 19q13.13-13.2, a region recently associated with a severe
autosomal recessive demyelinating neuropathy in a Lebanese family (Delague et al. 2000) and syntenic to the
location of Prx on murine chromosome 7 (Gillespie et al. 1997).
Introduction
Dejerine-Sottas neuropathy (DSN [MIM 145900]) and
Charcot-Marie-Tooth disease type 1 (CMT1 [MIM
118200]) represent genetically heterogeneous inherited
peripheral myelinopathies. These conditions constitute
part of a spectrum of neuropathy phenotypes ranging
in severity from congenital hypomyelinating neuropathy
(CHN [MIM 605253]) to adult-onset hereditary neu-
ropathy with liability to pressure palsies (HNPP [MIM
162500]) (Lupski and Garcia 2001). At least 15 genetic
loci and six genes have been associated with these dis-
orders; identified genetic causes include altered dosage
of peripheral myelin protein 22 (PMP22) and mutations
in one of the following genes: PMP22, the gap junction
protein b1 gene (GJB1), the myelin protein zero gene
(MPZ), the early growth response gene 2 (EGR2), the
myotubularin-related protein 2 gene (MTMR2), or the
N-myc downstream-regulated gene 1 (NDRG1) (Lupski
and Garcia 2001). These genes encode proteins of di-
verse functions: compact myelin structural proteins
(MPZ and PMP22), a noncompact myelin gap junction
protein (GJB1), signal transduction proteins (NDRG1
and MTMR2), and a transcription factor for late myelin
genes (EGR2). Both dominant mutant alleles (PMP22,
GJB1, MPZ, and EGR2) and recessive ones (MTMR2,
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NDRG1, PMP22, and EGR2) have been described. His-
torically considered an autosomal recessive disorder (De-
jerine and Sottas 1893), DSN has been associated pre-
dominantly, until this report, with de novo dominant
mutations in PMP22 (Roa et al. 1993),MPZ (Hayasaka
et al. 1993), or EGR2 (Timmerman et al. 1999), al-
though rare recessive mutations in PMP22 have also
been reported (Parman et al. 1999; Lupski 2000).
We hypothesized that the human orthologue of mu-
rine and rat Prx, which expresses L- and S-periaxin by
alternative intron retention (Dytrych et al. 1998), is a
good candidate gene for human inherited myelinopa-
thies. In murine embryonic Schwann cells, L-periaxin
initially is concentrated in the nuclei but redistributes
to the plasma membrane—predominantly adaxonal
with initiation of myelination, and then to the abax-
onal, Schmidt-Lanterman incisure, and paranodalmem-
branes with maturation of the myelin sheath (Scherer
et al. 1995; Sherman and Brophy 2000). In addition,
L-periaxin expression recapitulates this pattern follow-
ing crush injury (Scherer et al. 1995). This shift in per-
iaxin localization after the spiralization phase of mye-
lination suggests that periaxin participates in mem-
brane-protein interactions that are required to stabilize
the mature myelin sheath. As a cytoskeleton-asso-
ciated protein, L-periaxin may mediate such stabiliza-
tion by facilitating integration of extracellular signaling
through the cytoskeleton, which is essential for changes
in Schwann cell shape and regulation of gene expression
during axonal ensheathment (Fernandez-Valle et al.
1997; Tapon and Hall 1997). Such a signaling function
is supported by the observation that L-periaxin contains
a PDZ motif and a nuclear localization signal (Dytrych
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et al. 1998; Sherman and Brophy 2000). The PDZ do-
main, which consists of a nearly 90–amino acid protein-
binding motif that interacts with the carboxy termini
of plasma membrane proteins and with the cortical cy-
toskeleton, is named after the three proteins in which
it was first identified: the postsynaptic density protein
PSD-95, the Drosophila discs large tumor suppressor,
and the tight junction-associated protein ZO-1 (Fanning
and Anderson 1999). This domain has been implicated
in the assembly of signaling complexes at sites of cell-
cell contact.
Confirming the necessity of periaxin for maintenance
of the myelin sheath, Gillespie et al. (2000) recently
demonstrated that Prx/ mice ensheath and myelinate
peripheral axons apparently normally but subsequently
develop a severe demyelinating neuropathy associated
with allodynia (pain from non-noxious stimuli) and hy-
peralgesia (hypersensitivity to pain).
We report PRXmutations causing recessive DSN and
thus demonstrate the necessity of periaxin for mainte-
nance of human myelin sheaths. Furthermore, consis-
tent with the murine model, genotype-phenotype cor-
relation shows that these patients have a more
pronounced sensory involvement than do patients with
classical DSN or CMT.
Subjects and Methods
Human Subjects
All patients referred to this study by their primary
physician or neurologist received informed consent ap-
proved by the Institutional Review Board of Baylor Col-
lege of Medicine. We isolated DNA from the peripheral
blood of each patient and established lymphoblastoid
cell lines.
Human PRX cDNA Sequence
We defined the human PRX cDNA sequence corre-
sponding to L-periaxin by sequencing two expressed-
sequence tag (EST) clones (AW105547 and AW337783)
from the IMAGE consortium, sequencing reverse tran-
scriptase (RT) PCR and 5′ rapid amplification of cDNA
ends (RACE) products from human femoral nerve total
RNA, and sequencing 150–190 control chromosomes
across all coding exons. We isolated human femoral
nerve total RNA using Trizol (Life Technologies) (Chom-
czynski and Sacchi 1987). Prior to using the RNA for
RT-PCR (One-Step RT-PCR or Superscript II RNase H
Reverse Transcriptase, Life Technologies) or 5′ RACE
(GeneRacer Kit, Invitrogen), we treated it with ribo-
nuclease-free deoxyribonuclease I (Life Technologies) to
remove contaminating DNA. We cloned the products of
the 5′ RACE reaction into the TA vector (Invitrogen) to
separate and sequence the various products.
Mapping PRX
We screened the published rat Prx cDNA sequence
(Z29649) through the high-throughput genomic se-
quence database, using the BLAST algorithm. BAC clone
CTC-492K19 (AC010271) exhibited 83% identity to
the cDNA sequence. Using electronic PCR (ePCR), we
identified nine chromosome 19q STSs in BAC CTC-
492K19 and used these to place it on the chromosome
19 physical map. We also screened the RPCI-11 BAC
library with an overgo primer probe for PRX, isolated
two BACs (104E13 and 4K5) containing all coding ex-
ons of PRX, and used these to map PRX by FISH.
We performed FISH on metaphase preparations of hu-
man peripheral blood lymphocytes according to a mod-
ified procedure of Shaffer et al. (1997). In brief, 200 ng
of isolated BAC (104E13 and 4K5) DNA was labeled by
nick translation reaction using digoxigenin and 50 ng of
chromosome 19q13.4 control cosmid probe (F13141
from Lawrence Livermore National Laboratory flow-
sorted chromosome 19–specific cosmid library) using bi-
otin (Boehringer Mannheim). Biotin was detected with
fluorescein isothiocyanate-avidin (Vector Labs), and di-
goxigenin was detected with rhodamine–anti-digoxigenin
antibodies (Sigma). Chromosomes were counterstained
with DAPI diluted in Vectashield antifade (Vector Labs).
Cells were viewed under a Zeiss Axioskop fluorescence
microscope equipped with an appropriate filter combi-
nation. Monochromatic images were captured and pseu-
docolored using MacProbe 4.2.2 (Perceptive Scientific In-
struments) on a Power Macintosh G4 system.
Mutation Screening
By aligning the human genomic sequence from BAC
clone CTC-492K19 with the rat Prx cDNA, we identified
all coding exons; we confirmed each exon after charac-
terization of the human cDNAs. Using the Primer v3 pro-
gram, we designed primers to amplify exons and intronic
splice junctions and then screened amplified PCR prod-
ucts from patient genomic DNA for mutations, using the
WAVEDNA-fragment analysis system (Transgenomic). In
brief, by PCR we amplified the coding region of PRX
from 50 ng of patient genomic DNA, using the primers
listed in table 1 and Qiagen HotStarTaq. All forward
primers had a 21 M13 primer tail (TGTAAAACGA-
CGGCCAGT) and all reverse primers had a M13 reverse
tail (CAGGAAACAGCTATGACC). We generated each
PCR product, except that corresponding to exon 5, with
the following conditions: 95C for 15 min, 40 cycles of
amplification (95C for 30 s, 60C for 30 s, and 72C for
1 min), and 72C for 7 min. For exon 5, we added 1.5
U of Qiagen HotStarTaq, following the above protocol,
and then performed an additional 15 cycles of amplifi-
cation. To prepare the PCR products forDHPLCanalysis,
we pooled the products from every two patients and de-
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Table 1
Primer Pairs Used for Amplification of the PRX Coding Region
and Optimized DHPLC Column Temperatures for Each Amplicon
Primer Name Primer Pair
DHPLC
Column
Temperature
(C)
Exon 4:
Forward GTAAGCATGGCCTCCACCT 63
Reverse CTCCTTGCTGCCCTAGTCTG
Exon 5:
Forward ACCTGTTGAGCGCCAATG 66
Reverse CCCAAGGCAGATTCCTAACC
Exon 6:
Forward CGTGCAAGTGGGCAGAACTA 65
Reverse TGACAAGACAGAGGGCAAGG
Exon 7a:
Forward AATACCAGGTGGGGCTCTTC 63
Reverse CTCTAGGCAGGGAAGTGTGG
Exon 7b:
Forward AGCCGTGGGAATCCAGGT 63
Reverse TGACACTTTGGGCAGCTCTA
Exon 7c:
Forward CAGAGGTTCGACTCCCAGAG 62
Reverse GCCATCTCAGGCATTTTAGG
Exon 7d:
Forward CTGAGGTGAAACTCCCGAAG 63
Reverse GCAGAGTGAGAGAGGGGACA
Exon 7e:
Forward AAGCTAGGGAGGGCAGAGTC 63
Reverse AACTTGGGGAGAGCAAACCT
Exon 7f:
Forward CCTCAGGCAAGGTAGAGGTG 63
Reverse GTCACGGTGGGCATCTTAAA
Exon 7g:
Forward CAGGCTACAGGGTTCAGGTG 65
Reverse TTCTCTCTGACGGGGGACTT
Exon 7h:
Forward GTCCGCTTGCCACGTGTAG 62
Reverse GTACAGGCACTCCTGCCAGA
S-PRX C:
Forward CCGAGCCTTACAAAGTCTCCT NDa
Reverse AGTTTGGGGCAGAGAGGAAG
a ND p not determined.
natured the products at 95C for 5 min and reannealed
them by decreasing the temperature from 95C to 20C
over a period of 50 min. We analyzed these PCR products
for heteroduplexes by means of denaturing high-perform-
ance liquid chromatography (DHPLC), using a linear ace-
tonitrile gradient (flow rate of 0.9 ml/min, 2% slope [buf-
fer A, 0.1 M triethylammoniumacetate; buffer B, 0.1 M
triethylammoniumacetate/25% acetonitrile]; for column
temperatures, see table 1); we determined optimal column
temperatures empirically and identified potential hetero-
duplexes by visual inspection of elution chromatograms.
Using the Qiagen 96-PCR purification kit (Qiagen),
we purified patient PCR products having an abnormal
elution profile and appropriate PCR products from rel-
atives’ chromosomes and control chromosomes and se-
quenced them with dye-primer chemistry (PE Applied
Biosystems), using an ABI377 automated sequencer (PE
Applied Biosystems). We aligned the resulting sequences
and evaluated mutations with the Sequencher sequence
alignment program (ACGT Codes). We numbered the
PRX cDNA sequence beginning with the adenine of the
presumed initiating methionine and describedmutations
according to den Dunnen and Antonarakis (2000).
Results
Mapping and Characterization of PRX
We mapped PRX in the human genome, defined its
cDNA sequence and gene structure, and subsequently
evaluated the tissue expression profile of PRX mRNA.
By FISH and ePCR (Schuler 1997), the BAC containing
PRX maps to chromosome 19q13.13-q13.2 between
D19S324 and D19S223 (fig. 1a). This places PRX
within a recently mapped interval for an autosomal re-
cessive myelinopathy (Delague et al. 2000). Sequencing
of RT-PCR and 5′ RACE products from femoral nerve
mRNA and available EST clones defined two PRX tran-
scripts of 4853 and 5502 bp, excluding the polyA tails.
The shorter mRNA is transcribed from seven exons, and
the deduced coding sequence extends from exon 4
through exon 7 (fig. 1b). The longer transcript arises by
retention of intron 6 (figs. 1b, 1c, and 2); this introduces
a stop codon and results in a truncated protein with an
intron-encoded carboxyl terminus of 21 amino acids.
As observed in mice and rats, the amino acid sequence
deduced from the shorter cDNA sequence contains a
PDZ domain (amino acids 14–98), a highly basic do-
main (amino acids 118–194) that functions as a nuclear
localization signal in mice, a repeat domain (amino acids
400–700), and an acidic domain (amino acids 1098–
1235) (figs. 1b and 2) (Gillespie et al. 1994; Dytrych et
al. 1998; Sherman and Brophy 2000). The amino acid
sequence deduced from the longer cDNA sequence con-
tains only the PDZmotif. Hybridization of several Clon-
tech multitissue northern blots with a probe from exon
7 revealed expression of a 5.1-kb PRX mRNA in all
tissues examined; mRNA from spinal cord, a tissue with
many peripheral nerve roots, showed strongest hybrid-
ization of 5.1- and 5.6-kb bands (fig. 1c). In contrast to
the nearly equal expression of each mRNA in mice (Dy-
trych et al. 1998), the 5.6-kb mRNA appears less abun-
dant in humans. RT-PCR confirmed the peripheral
nerve–tissue predominant expression (data not shown).
PRX Mutation Analysis in Neuropathy Patients
Using DHPLC, we screened each coding exon of PRX
for mutations in 168 patients with peripheral neurop-
athy who had tested negative for mutations involving
PMP22, MPZ, GJB1, EGR2, or MTMR2. We se-
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Figure 1 Mapping of PRX and expression of PRXmRNA. a, By ePCR, BAC CTC-492K19, which contains PRX,maps betweenD19S324
and D19S223. We confirmed this by metaphase FISH; cohybridization with BAC RPCI-11 104E13 (red) and chromosome 19 control cosmid
F13141 (green) assigned PRX to 19q13.13-q13.2 (arrow, ideogram in accord with the International System forHumanCytogeneticNomenclature
[1995]). b, Diagram showing the two PRX mRNAs resulting from alternative retention of intron 6. The large periaxin protein (L-PRX) is
encoded by the shorter spliced mRNA, and the smaller periaxin protein (S-PRX) is encoded by the longer mRNA retaining intron 6. Coding
regions are shaded. c, Northern analysis showing that both the 5.1- and 5.6-kb PRX mRNAs were most abundant in spinal cord, a tissue with
many peripheral nerve roots.
quenced those PCR amplicons that gave an abnormal
DHPLC elution profile. Patient 851 of family HOU297
is compound heterozygous for deletion 2787DC and
transition 2857CrT. By conceptual translation, 2787DC
causes a frameshift following amino acid S929 and
terminates the protein at codon 957 (S929fsX957),
whereas 2857CrT causes the nonsense mutation
R953X (figs. 3 and 4). We did not observe 2787DC or
2857CrT in control chromosomes (fig. 4). The patient
1461 in family HOU579 is compound heterozygous for
deletion 2289DT and a 1102CrT transition causing the
nonsense mutation R368X; 2289DT results in a frame-
shift after amino acid V763 and terminates the protein
at codon 774 (V763fsX774; fig. 3). The unaffected par-
ents and son of family HOU579 are all heterozygous
carriers of a PRX mutant allele (fig. 3). We did not
observe 2289DT or 1102CrT in control chromosomes
(fig. 4). Patient 1136 of family HOU418 was homozy-
gous for deletion 2787DC, the same deletion observed
in patient 851 of HOU297. The unaffected parents, sis-
ters, and son of this patient are all heterozygous carriers
of this deletion on one PRX allele (figs. 3 and 4); al-
though unaware of consanguinity, both parents hailed
from the same small village in Vietnam.
Other PRX sequence variants identified in patients
and controls are shown in table 2. Most of these likely
represent benign polymorphic variants, but whether the
alleles identified in only one control chromosome rep-
resent rare polymorphisms or a recessive carrier state
remains to be determined.
Phenotype of Patients with PRX Loss-of-Function
Mutations
The clinical features of peripheral neuropathy in pa-
tients with autosomal recessive PRXmutations are com-
parable to those observed in the 19q13 linked family
and the homozygous knockout mice (table 3) (Delague
Figure 2 Comparison of human, murine, and rat L-periaxin (a) and S-periaxin (b) amino acid sequences. a, Human L-periaxin has ∼78%
and ∼73% sequence identity with the murine and rat proteins, respectively. The PDZ domain, tripartite nuclear localization signal (NLS1,
NLS2, and NLS3), repeat domain, and acidic domain previously characterized in mice and rats are conserved in humans. Arrowheads indicate
mutations identified in patients. b, S- and L-periaxin share a common amino terminal, but retention of intron 6 in the mRNA encoding S-
periaxin results in a truncated protein with 20 amino acids encoded within the intron (blackened box). Identical amino acids are indicated by
a colon (:), gaps by a dash (—) and stop codons by an asterisk (*).
Figure 3 Chromatograms of PRX alterations identified in three families. Families HOU297, HOU579, and HOU418 exhibit autosomal
recessive inheritance. Blackened symbols indicate DSN. Patient 851, from family HOU297, is compound heterozygous for mutations S929fsX957
and R953X; her older unaffected son is heterozygous for R953X (data not shown). Patient 1461, from familyHOU579, is compoundheterozygous
for mutations V763fsX774 and R368X; her unaffected brother is heterozygous for V763fsX774 (data not shown). Patient 1136 from family
HOU418 has the homozygous mutation S929fsX957; her two unaffected sisters and her son are heterozygous for this mutation (data not
shown).
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Table 2
Alterations Occurring in North American Control
Chromosomes or Unaffected Family Members
Alteration
Frequency in Control
Chromosomesa
3775GrA E1259K 0/190b
1216GrA A406T 1/178
4075-4077D E1359del 1/150
1483GrC E495Q 2/184
3394ArG R1132G 6/182
3248CrG P1083R 24/182
2763ArG I921M 37/190
2645CrT A882V 45/190
306CrT T102T ND
1491CrG P497P ND
2655TrC P885P ND
a ND p not determined.
b Observed in an unaffected sibling.
Figure 4 Mutations identified in PRX. The location of mutations within L-periaxin is indicated in the diagram at the top by the arrows.
The clinical phenotype of each patient, their mutations, and the frequency of their mutations in North American control chromosomes are
listed below.
et al. 2000; Gillespie et al. 2000). In each patient, ob-
jective findings include markedly reduced nerve-conduc-
tion velocities and onion-bulb formation (OBFs) on neu-
ropathology. These patients have a more severe sensory
component than is usually seen with typical DSN or
CMT1.
Discussion
Consistent with the Prx/ mice, these three families es-
tablish that putative loss-of-function mutations in PRX
cause autosomal recessive DSN (fig. 4). The nonsense
and frameshift mutations delete the carboxyl portion of
L-periaxin, including the acidic domain. The function of
this portion of L-periaxin has not been defined, although
acidic domains commonly mediate protein-protein in-
teractions. Loss of this domain, therefore, might inhibit
binding of L-periaxin to the cytoskeleton or might pre-
clude L-periaxin from interacting with proteins essential
for transmission of extracellular signals.
PRX mutations are a significant cause of apparently
sporadic and autosomal recessive DSN. Of 20 unrelated
DSN patients in our cohort, 3 inherited two recessive
mutant PRX alleles; by comparison, 4, 3, and 2 DSN
patients of the 20 had de novo heterozygous causative
mutations in MPZ, PMP22, and EGR2, respectively.
Moreover, because HOU297, HOU579, and HOU418
are respectively of North American Hispanic, Northern
European (English-German-Polish), and Vietnamese
ethnicities, we suggest that PRX mutations are a sig-
nificant cause of DSN in most populations. These two
observations imply that identification of PRXmutations
will be important for the diagnosis and recurrence-risk
counseling of DSN patients and their families.
We previously hypothesized that, because mutations
of the transcription factor EGR2 cause myelinopathies,
mutation of genes regulated by EGR2 might also result
in myelinopathies (Warner et al. 1998). J. Milbrandt
and coworkers have shown, consistent with this claim,
that EGR2 regulates PRX expression (personal com-
munication). This observation suggests that other genes
regulated by EGR2 may also have mutations causing
CMT1 or related myelinopathies and raises the possi-
bility that the expression of proteins interacting with L-
periaxin may also be regulated by EGR2.
The association of mutations in PRX with peripheral
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Table 3
Clinical Features of Patients with Myelinopathy Secondary to PRX Mutations
CHARACTERISTIC
FAMILY/PATIENTa
CMT4F/19q13.1-q13.3a Prx/ MICEbHOU297/851 HOU579/1461 HOU418/1136
Current age (years) 46 6 31
Sex Female Female Female
Age at onset (years) !7 1.5 1 Early childhood 4–6 weeks
Inheritance pattern Autosomal recessive Autosomal recessive Autosomal recessive Autosomal recessive Autosomal recessive
Motor involvement Distal dominant, severe Distal dominant, severe Distal dominant, severe Distal dominant, severe Severe weakness
Sensory loss Severe Severe Severe Severe Severe
Sensory ataxia No Yes Yes Yes Unsteady gait
Dysesthesia None None Yes Yes Yes
Foot deformity Pes cavus None Pes cavus Pes cavus, Pes equinovarus Not described
Motor nerve con-
duction velocity
3 m/sec Undetectable 2.1 m/sec in median nerve Undetectable Severely delayed
Peripheral nerve
histopathology
NA Hypomyelination, dys-
myelination, OBF
NA Severe loss of MF, OBF Demyelination,
thick and thin
myelin sheaths,
loss of MF, OBF
NOTE.—NA p not available; MF p myelinated fibers; OBF p onion-bulb formation.
a Delague et al. (2000).
b Gillespie et al. (2000).
neuropathy not only identifies another genetic cause for
the CMT1 spectrum of myelinopathies but also provides
further insights into the molecular mechanisms for these
diseases. The interaction among L-periaxin, the cytoske-
leton, and a membrane complex is reminiscent of the
interactions among the proteins of the dystrophin-sar-
coglycan complex (Cohen and Campbell 2000) and the
signaling complexes organized by other PDZ domain
proteins (Montell 2000). We hypothesize that mutations
in cytoskeletal and membrane proteins interacting with
L-periaxin may also cause CMT or related neuropathies.
Acknowledgments
We thank the families described for their cooperation. H.T.
is a recipient of a postdoctoral fellowship from the Charcot-
Marie-Tooth Association. This study was supported in part by
grants from the National Institute of Diabetes, Digestive, and
Kidney Diseases, NIH (K08 DK02738, to C.F.B.), and from
the National Institute of Neurological Disorders and Stroke
(R01 NS27042) and the Muscular Dystrophy Association (to
J.R.L.).
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
BLAST, http://www.ncbi.nlm.nih.gov/BLAST/
Chromosome 19 physical map, http://greengenes.llnl.gov//
genome/html/chrom_map.html
Electronic PCR, http://www.ncbi.nlm.nih.gov/genome/sts/epcr
.cgi
GenBank, http://www.ncbi.nlm.nih.gov/Genbank (for human
PRX mRNA sequence encoding S-periaxin [AF321192]
and human PRX mRNA sequence encoding L-periaxin
[AF321191])
HUGO Gene Nomenclature Committee, http://www.gene.ucl
.ac.uk/nomenclature/ (for registered gene name PRX)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for CMT1 [MIM 118200], DSN
[MIM 145900], CHN [MIM 605253], and HNPP [MIM
162500])
Primer v3 program, http://www-genome.wi.mit.edu/cgi-bin/
primer/primer3_www.cgi
References
Chomczynski P, Sacchi N (1987) Single-step method of RNA
isolation by acid guanidinium thiocyanate-phenol-chloro-
form extraction. Anal Biochem 162:156–159
Cohen RD, Campbell KP (2000) Molecular basis of muscular
dystrophies. Muscle Nerve 23:1456–1471
Dejerine J, Sottas J (1893) Sur la ne´vrite interstitielle hyper-
trophique et progressive de l’enfance. Comp Rend Seanc Soc
Biol 45:63–96
Delague V, Bareil C, Tuffery S, Bouvagnet P, Chouery E,
Koussa S, Maisonobe T, Loiselet J, Megarbane A, Claustres
M (2000) Mapping of a new locus for autosomal recessive
demyelinating Charcot-Marie-Tooth disease to 19q13.1-
13.3 in a large consanguineous Lebanese family: exclusion
of MAG as a candidate gene. Am J Hum Genet 67:236–243
den Dunnen JT, Antonarakis SE (2000) Mutation nomencla-
ture extensions and suggestions to describe complex mu-
tations: a discussion. Hum Mutat 15:7–12
Dytrych L, Sherman DL, Gillespie CS, Brophy PJ (1998) Two
PDZ domain proteins encoded by the murine periaxin gene
are the result of alternative intron retention and are differ-
entially targeted in Schwann cells. J Biol Chem 273:
5794–5800
Fanning AS, Anderson JM (1999) Protein modules as organ-
Boerkoel et al.: PRX Mutations Cause Recessive DSN 333
izers of membrane structure. Curr Opin Cell Biol 11:
432–439
Fernandez-Valle C, Gorman D, Gomez AM, BungeMB (1997)
Actin plays a role in both changes in cell shape and gene-
expression associated with Schwann cell myelination. J Neu-
rosci 17:241–250
Gillespie CS, Lee M, Fantes JF, Brophy PJ (1997) The gene
encoding the Schwann cell protein periaxin localizes on
mouse chromosome 7 (Prx). Genomics 41:297–298
Gillespie CS, Sherman DL, Blair GE, Brophy PJ (1994) Per-
iaxin, a novel protein of myelinating Schwann cells with a
possible role in axonal ensheathment. Neuron 12:497–508
Gillespie CS, Sherman DL, Fleetwood-Walker SM, Cottrell DF,
Tait S, Garry EM, Wallace VC, Ure J, Griffiths IR, Smith
A, Brophy PJ (2000) Peripheral demyelination and neuro-
pathic pain behavior in periaxin-deficient mice. Neuron 26:
523–531
Hayasaka K, Himoro M, Sawaishi Y, Nanao K, Takahashi T,
Takada G, Nicholson GA, Ouvrier RA, Tachi N (1993) De
novo mutation of the myelin P0 gene in Dejerine-Sottas dis-
ease (hereditary motor and sensory neuropathy type III). Nat
Genet 5:266–268
Lupski JR (2000) Recessive Charcot-Marie-Tooth disease. Ann
Neurol 47:6–8
Lupski JR, Garcia CA (2001) Charcot-Marie-Tooth peripheral
neuropathies and related disorders. In: Scriver CR, Beaudet
AL, Sly WS, Valle D, Vogelstein B, Childs B (eds) The met-
abolic and molecular bases of inherited disease. McGraw-
Hill, New York, pp 5759–5788
Montell C (2000) A PDZ protein ushers in new links. Nat
Genet 26:6–7
Parman Y, Plante-Bordeneuve V, Guiochon-Mantel A, Eraksoy
M, Said G (1999) Recessive inheritance of a new point mu-
tation of the PMP22 gene in Dejerine-Sottas disease. Ann
Neurol 45:518–522
Roa BB, Dyck PJ, Marks HG, Chance PF, Lupski JR (1993)
Dejerine-Sottas syndrome associated with point mutation in
the peripheral myelin protein 22 (PMP22) gene. Nat Genet
5:269–273
Scherer SS, Xu Y-t, Bannerman PGC, Sherman DL, Brophy PJ
(1995) Periaxin expression in myelinating Schwann cells:
modulation by axon-glial interactions and polarized local-
ization during development. Development 121:4265–4273
Schuler GD (1997) Sequence mapping by electronic PCR. Ge-
nome Res 7:541–550
Shaffer LG, Kennedy GM, Spikes AS, Lupski JR (1997) Di-
agnosis of CMT1A duplications and HNPP deletions by
interphase FISH: implications for testing in the cytogenetics
laboratory. Am J Med Genet 69:325–331
Sherman DL, Brophy PJ (2000) A tripartite nuclear localiza-
tion signal in the PDZ-domain protein L-periaxin. J Biol
Chem 275:4537–4540
TaponN, Hall A (1997) Rho, Rac and Cdc42GTPases regulate
the organization of the actin cytoskeleton. Curr Opin Cell
Biol 9:86–92
Timmerman V, De Jonghe P, Ceuterick C, De Vriendt E, Lof-
gren A, Nelis E, Warner LE, Lupski JR, Martin JJ, Van
Broeckhoven C (1999) Novel missense mutation in the early
growth response 2 gene associated with Dejerine-Sottas syn-
drome phenotype. Neurology 52:1827–1832
Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L,
Koob KG, Lupski JR (1998) Mutations in the early growth
response 2 (EGR2) gene are associated with hereditary mye-
linopathies. Nat Genet 18:382–384
